BioSpace News Archive

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the fourth quarter and year ended December 31, 2023 and provided a business update.

Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, reported financial results for the quarter and year ended December 31, 2023.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia.

Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA® (guselkumab) for treatment of adults with moderately to severely active ulcerative colitis (UC).

Arcus Biosciences, Inc., announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 13,800 shares of the Company’s common stock at an exercise price per share of $17.99, which was the closing price on March 8, 2024, and restricted stock units to acquire a total of 6,900 shares of the Company’s common stock.

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to report fourth quarter and full year 2023 financial results on March 14, 2024.

Today, The American Diabetes Association ® (ADA) and DaVita (NYSE: DVA), a leading provider of kidney care services, announced the expansion of a multi-year collaboration, focused on advancing chronic disease prevention, specifically addressing two of the most prevalent chronic conditions in the U.S. — diabetes and chronic kidney disease (CKD).

TriSalus Life Sciences® Inc. (Nasdaq: TLSI) announced today that the Company will host a conference call and webcast on April 1, 2024, at 9:00 a.m. ET to discuss financial results for the fourth quarter and full year ended December 31, 2023, and provide a business update.

Cognition Therapeutics, Inc. announced that it has priced an underwritten public offering of 6,571,428 shares of its common stock at an offering price of $1.75 per share of common stock.

Belite Bio, Inc announced its audited financial results for full-year 2023 and the unaudited and unreviewed financial results for the quarter ended December 31, 2023, and provided a business update.